Testing version — LOERadar is in active testing. Features and data may change.
VIDEX EC (DIDANOSINE) | LOERadar
VIDEX EC
NDA
DIDANOSINE | N021183 | BRISTOL MYERS SQUIBB CO
4 strengths0 unique patents0 unique exclusivities
PTAB Proceedings
No IPR/PGR/CBM challenges found at the Patent Trial and Appeal Board
Hatch-Waxman Litigation
Para IV certification filed but no ANDA patent litigation cases (NOS 835) matched from PACER. Litigation may be pending or filed under a different caption.
Citizen Petitions
No FDA citizen petitions matched from Regulations.gov
Products (4)
Sort:
#001 — 125MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**
RLD
0 patents0 exclusivities▴
CAPSULE, DELAYED REL PELLETS;ORAL | Approved: Oct 31, 2000
No patent or exclusivity listings for this strength.
#002 — 200MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**
RLD
0 patents0 exclusivities▾
CAPSULE, DELAYED REL PELLETS;ORAL | Approved: Oct 31, 2000
#003 — 250MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**
RLD
0 patents0 exclusivities▾
CAPSULE, DELAYED REL PELLETS;ORAL | Approved: Oct 31, 2000
#004 — 400MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**
RLD
0 patents0 exclusivities▾
CAPSULE, DELAYED REL PELLETS;ORAL | Approved: Oct 31, 2000